John Polzer

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes

Joanne Sloan‐Lancaster, Eyas Abu-Raddad, John Polzer et al. · Diabetes Care · 2013 · 178 citations · Full text

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling et al. · Clinical Cancer Research · 2014 · 109 citations

A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer

Ravi Salgia, John R. Stille, R Weaver et al. · Lung Cancer · 2017 · 74 citations

Medicine, Pathology, Bronchial Neoplasm +6

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

John D. Hainsworth, James A. Reeves, Joseph R. Mace et al. · Targeted Oncology · 2016 · 59 citations

Urology, Open-label Phase 2, Genitourinary Cancer +7

Age, breed, sex and seasonality as risk factors for equine laminitis

John Polzer, Margaret R. Slater · Preventive Veterinary Medicine · 1997 · 44 citations

Animal Science, Animal Health, Veterinary Science +7